Gray Matter Amyloid Beta Quantification via White Matter Suppression

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current diagnostic imaging methods for amyloid deposition in the brain, particularly for Alzheimer's disease, face challenges in differentiating between gray and white matter uptake due to the dominance of white matter in brain scans, leading to difficulties in accurately quantifying amyloid beta (Aβ) deposition using new PET radiotracers like [18F]-Flutemetamol, [18F]-Florbetaben, and [18F]-Florbetapir.

Innovation Solution

An imaging workstation processes PET brain images by registering them to a common space defined by an MRI template, segmenting gray matter, and suppressing radiotracer uptake outside this area, using a probability map to weight voxel values and project them onto a brain surface, thereby isolating and enhancing the visualization of gray matter amyloid beta.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If radiotracer uptake is visualized in the entire brain, then white matter uptake is captured, but gray matter amyloid beta deposition cannot be accurately differentiated

Engineering Contradiction:
Improvegray matter amyloid beta quantificationVSAvoidwhite matter signal interference
Core Design Contradiction:
Measurement precisionVSLoss of information

Solution Approach 1:

The brain is segmented into gray matter and white matter regions using anatomical MRI data. This segmentation allows separate analysis of radiotracer uptake in each tissue type, enabling accurate quantification of gray matter amyloid beta deposition while excluding confounding white matter signal.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The white matter component is extracted and removed from the combined brain signal. By isolating and eliminating the white matter contribution, the method retrieves pure gray matter amyloid beta signal, resolving the interference problem.

Inventive Principle:
Principle #2Taking out (Extraction)

2Reliability

If standard PET imaging is used, then overall radiotracer distribution is visible, but diagnostic accuracy for Alzheimer's is reduced due to white matter dominance

Engineering Contradiction:
ImproveAlzheimer's diagnosis accuracyVSAvoidwhite matter uptake interference
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The method uses the known anatomical structure of white matter (obtained from MRI) to identify and remove its harmful interfering signal. By converting the anatomical knowledge into a segmentation mask, the harmful white matter uptake is systematically eliminated, improving diagnostic reliability.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

Anatomical MRI data serves as an intermediary tool that facilitates the separation of gray and white matter signals. The MRI provides structural information that acts as a mediator to guide the extraction and removal of white matter interference from the PET functional data.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Measurement precision

If arterial blood sampling kinetic modeling is used, then accurate Aβ quantification is achieved, but clinical practicality is reduced

Engineering Contradiction:
ImproveAβ quantification accuracyVSAvoidclinical workflow complexity
Core Design Contradiction:
Measurement precisionVSEase of operation

Solution Approach 1:

The method extracts and removes the need for complex arterial blood sampling and kinetic modeling by directly analyzing static PET images with white matter suppression. This simplification maintains adequate quantification accuracy while dramatically improving clinical practicality.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The approach changes the imaging parameters from dynamic time-series acquisition with arterial sampling to static image acquisition with post-processing white matter suppression. This parameter change simplifies the clinical workflow while preserving essential diagnostic information.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP2747658B1Method to compute and present brain amyloid in gray matter
Publication Date: 2020.01.15 KONINKLIJKE PHILIPS NV
  • EP2747658B1 patent drawingFigure 1
  • EP2747658B1 patent drawingFigure 2
  • EP2747658B1 patent drawingFigure 3

AI summary

An imaging work station (20) includes one or more processors programmed to receive (170)an image depicting a distribution of a radiotracer in a brain or other region of interest. The radiotracer includes at least one of [18F]-Flutemetamol, [18F]-Florbetaben, and [18F]-Florbetapir which highlights amyloid deposits. The image and a template or an MRI image of the region of interest which includes a segmented anatomical feature, such as gray matter, are registered (180)to a common space. A volume representation of the image which depicts the distribution of the radiotracer in the segmented gray matter and suppresses the radiotracer outside of the segmented anatomical feature in white matter is extracted (210).